The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With Hypoxemia

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

January 1, 2023

Study Completion Date

January 10, 2023

Conditions
Oxygen DeficiencyPulmonary Arterial HypertensionCTEPH
Interventions
DRUG

Oxygen

Study medication will be oxygen (O2) in diverse concentrations, titrated until a SaO2\>90% or pO2 \>60 mmHg is achieved, for 20 patients vs. no supplemental O2 for 20 patients over 90 ± 7 days. Patients of the control group will be offered to participate in the interventional treatment arm after they have terminated the control period (partial cross-over; secondary intervention group). After the end of the study it is up to the judgment of the investigator to prescribe oxygen to all patients who might benefit from the treatment.

Trial Locations (1)

69126

Centre for pulmonary hypertension of the Thoraxclinic at the University Hospital Heidelberg, Heidelberg

All Listed Sponsors
lead

Heidelberg University

OTHER

NCT04207593 - The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With Hypoxemia | Biotech Hunter | Biotech Hunter